CRYGA

Across TCGA pan-cancer cohorts, CRYGA Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CRYGA data layer compared with 11 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher CRYGA Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CRYGA expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

LUSC, LUAD, and LIHC are the cancer types where CRYGA Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.192	0.745	<.001	24	view →
LUAD	OS	Median	All	0.174	0.814	<.001	24	view →
LIHC	OS	Median	All	0.198	0.777	.006	18	view →
KIRC	OS	Median	All	0.122	0.629	.019	12	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
STAD	OS	Median	IV	1.000	0.299	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CRYGA–LUSC (OS)

Open the LUSC breakdown →